Effects of Tribulus Terrestris on Sexual Function in Post-menopausal Women

Study of the Effects of Tribulus Terrestris on Sexuality in Postmenopausal Women

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01407445

Enrollment

Registered

2011-08-02

Start date

2009-01-31

Completion date

2011-05-31

Last updated

2015-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sexual Functions and Problems in the Adult

Keywords

Menopause, Sexual dysfunction, Tribulus, Sexuality, Phytotherapeutic Drugs

Brief summary

Objective: To study the effects of Tribulus terrestris on sexuality in postmenopausal women.

Detailed description

Sexuality is an integral part of every personality, influence thoughts, feelings, actions, integrations, and therefore the physical and mental health. It is estimated that 43% of women have at least one complaint of sexual problem. Disorders of desire and arousal are among the most common problems found in gynecologic practice. Medicinal plants have been used for therapeutic purposes for thousands of years, and aphrodisiac properties described in several plants. Tribulus terrestris is a plant indigenous to India, recommended in the treatment of infertility, low libido and impotence, and its main active ingredient protodioscin (PTN).

Interventions

DRUGPlacebo

1 tablet/ oral/ 3 times a day for 90 days

DRUGTribulus terrestris

1 tablet of 250mg/ oral/ 3 times a day for 90 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

40 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Women past menopause, with full autonomy, at least one year of amenorrhea and FSH\> 30 mIU / mL. * Sexually active * Partner is stable and without sexual difficulties * Carrier sexual abuse (desire, arousal, orgasm and dyspareunia)

Exclusion criteria

* Women on hormone therapy within the preceding 12 months * Women without sexual activity * With diabetes mellitus * Patients with cognitive impairment * Patients with hormone-dependent tumor * History of psychiatric illness * Patients with liver disease * Patients with kidney disease * Users of drugs with proven to decrease sexual desire * Cardivascular disease, renal disease.

Design outcomes

Primary

Measure	Time frame	Description
Sexual function in post-menopausal women	90 days	Based the questionnaires Golombok-Rust Inventory of Sexual Satisfaction (GRISS) and Sexual Quotient - female version (SQF).

Secondary

Measure	Time frame
Female Intervention Efficacy Index (FIEI)	3 months

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026